Journal article · 2026 · Open access
Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?
Targetome, 2(1), 0 · Published 1 January 2026 · DOI 10.48130/targetome-0026-0004
In brief
“Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?” is a 2026 journal article by Yun Chen, published in Targetome. OpenAlex counts 1 citations as of 18 November 2026, which puts it in the top 9% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Targetome.
- Citations
- 1
- Most cited in
- 2026 (1)
- Field-weighted impact
- 1.39
- References
- 58
- Authors
- 1
Abstract
A new study published inNature Neurosciencedemonstrated that Fc effector function is essential for amyloid aggregate clearance during lecanemab treatment, a recently FDA-approved therapy for Alzheimer's disease. These findings underscore the requirement for intact Fc-mediated activity to achieve therapeutic efficacy. In addition, single-cell RNA sequencing identified microglia transcriptomic changes that are unique to lecanemab treatment and extend beyond previously characterized microglial activation signatures. Together with a retrospective review of anti-amyloid antibody development and related mechanisms, this commentary provides important insights into new directions for the design of next-generation therapies for Alzheimer's disease.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Chen, Y. (2026). Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand? Targetome, 2(1), 0. https://doi.org/10.48130/targetome-0026-0004
MLA 9
Chen, Yun. “Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?” Targetome, vol. 2, no. 1, 2026, p. 0. https://doi.org/10.48130/targetome-0026-0004.
Chicago
Chen, Yun. 2026. “Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?” Targetome 2 (1): 0. https://doi.org/10.48130/targetome-0026-0004.
Harvard
Chen, Y. (2026) ‘Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?’, Targetome, 2(1), p. 0. doi:10.48130/targetome-0026-0004.
IEEE
Y. Chen, “Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?,” Targetome, vol. 2, no. 1, p. 0, 2026, doi: 10.48130/targetome-0026-0004.
BibTeX
@article{chen2026anti,
title = {{Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?}},
author = {Chen, Yun},
journal = {Targetome},
year = {2026},
volume = {2},
number = {1},
pages = {0},
doi = {10.48130/targetome-0026-0004},
url = {https://doi.org/10.48130/targetome-0026-0004}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- anti-amyloid antibodies
- lecanemab
- Fc effector functions
- microglial activation
- single-cell RNA sequencing
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Chen, Y. (2026). Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand? Targetome, 2(1), 0. https://doi.org/10.48130/targetome-0026-0004
How many times has this paper been cited?
1 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Targetome: sign in and open the PDF from this page.
Who wrote this paper?
Yun Chen.
What is the DOI of this paper?
10.48130/targetome-0026-0004, permanently at https://doi.org/10.48130/targetome-0026-0004. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.